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Platelets are potent antibody- and complement-dependent cytotoxic effector cells.  We showed 
previously that a single platelet can lyse a target cell sensitized with immunoglobulin G (IgG) 
and  complement components  up  to  C3  (C,,o3b  denotes the  target  cell-bound  fragment  of 
complement up to C3; the precise nature of the bound C3 fragment has not been established), 
and that the complete cytotoxic system capable of specific recognition and lysis resides in platelet 
membranes.  To define the components of platelet membranes required for cytotoxicity, a set 
of inhibitors of phospholipase A2 (PLA2) that act by different chemical mechanisms was tested. 
The lytic reaction is blocked at appropriate concentrations of bromophenacylbromide, mepacrine, 
and manoalide. When platelets are treated with bromophenacylbromide, inhibition of cytolytic 
activity and that of PLA2 enzymatic activity occur in parallel.  Platelets release arachidonate when 
incubated with  target  cells bearing IgG and C~3b,  confirming that FcyR and complement 
receptor  trigger  both  PLA2  action  and  efficient lysis.  Inhibition  by  thimerosal  of a  reverse 
reaction, i.e., reacylation catalyzed by acyltransferase,  causes increased target cell lysis, presumably 
by increasing the products of PLA2 action. Platelet cytotoxicity is increased when platelets are 
pretreated with some products of PLA2: exogenous lysophospholipids and not free arachidonic 
acid increase cytotoxicity. Electron microscopy suggests that platelets and target ceils may fuse, 
possibly as a result of the formation of lysophospholipids which are well-known membrane fusogens. 
Fixation with paraformaldehyde does not affect platelet cytotoxicity, suggesting that the complete 
cytotoxic system resides as a preformed complex in platelet membranes. The results indicate that 
platelet  membrane-associated  PLAz,  together  with  receptors  for  Fc  and  complement,  are 
required for platelet cytotoxicity. 
lthough  small in  size and lacking nuclei,  platelets are 
potent cytotoxic effector cells present in numbers and 
total surface area that are vast in comparison with other blood- 
borne  immune effectors  (1,  2).  Both  mouse  and  human 
platelets bear receptors for the constant domains of IgG mol- 
ecules (Fc3'R) and CR (3-6). Platelets are antibody-dependent 
tumoricidal effectors of the immune system in vivo (7-9). 
They also have been shown to lyse IgE-coated schistosomulae 
(10)  and Brugia malayi microfilariae (11). In the absence of 
specific antibody, platelets can lyse Toxoptasma gondii (12) and 
tumor  cells  (13)  in  vitro.  In  these  antibody-independent 
processes,  the activation of phospholipase A2 (PLA2) 1 and 
the involvement of arachidonic acid metabolites have been 
implicated. 
1Abbreviations used in  this paper: BAP, bromoacetophenone; BPB, 
bromophenacylbromide;  EMTS, ethyl mercurithiosalicylate;  PAF, platelet- 
activating factor; PLA2, phospholipase  A2. 
An  experimental  system  facilitating  study  of  platelet- 
mediated cytotoxicity in vitro was developed by Soper et al. 
(1). Antibody-coated sheep erythrocytes were efficiently lysed 
in platelet-rich plasma. We subsequently showed that washed 
platelets specifically lyse target cells coated with IgG2a, IgG2b, 
or IgG3 antibody together with complement C"o3b.  The 
lysis is a single hit phenomenon, as a single platelet can lyse 
a target cell. The complete system capable of recognition and 
lysis is localized in platelet membranes (2).  The cytotoxic 
system includes Fc receptors (Fcy2aR, Fcy2bR, and Fc3,3R), 
a still unidentified CR that is not CR1 (14), and unidentified 
lytic effector molecules. Our previous experiments showed 
that some mechanisms of cytotoxicity used by other cells, 
such as the generation of toxic oxygen metabolites, release 
of proteases, or formation of active granular cytolysin, are 
not involved in platelet-mediated, antibody-dependent cyto- 
toxicity (2). 
We became interested in elucidating the role of membrane 
lipids and proteins in the lytic reaction, since the complete 
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tioned  above,  PLA2  activation  has been  implicated  in  the 
mechanism of cytotoxicity by platelets in the absence of anti- 
body (12,  13).  Furthermore,  several reports have indicated 
that ligation of Fc3'2bR is correlated with PLA2 activation 
in human B cells and mouse macrophages (15-17). FceR and 
some FcyR share common subunits as part of their multichain 
structures  (18),  and  activation  of PLA2  has  been  demon- 
strated upon FcER ligation in mast cells and basophils (19). 
It  should be noted that  primary sequences of Fc receptors 
purified to date do not encode a known lipase (20), but in 
some cases bear homology with the acetylcholine receptor, 
consistent with a demonstrated ionophore activity upon FcR 
ligation (20, 21). Activation of PLA2 has also been proposed 
to occur in cytotoxicity mediated by NK cells (22-24).  We 
therefore  sought  to  establish  a  direct  association  between 
PLA2  activation  and  the  cytotoxicity induced  by platelet 
receptors for IgG and complement. 
Materials  and Methods 
Reagents and Buffers.  All reagents and buffers were prepared or 
purchased as previously described in detail (2), except where noted. 
Bromophenacylbromide (BPB), bromoacetophenone (BAP),  and 
ethyl mercurithiosalicylate (EMTS; thimerosal) were purchased from 
Sigma Chemical Co. (St. Louis, MO); mepacrine from ICN Bio- 
medicals  (Costa Mesa,  CA); and manoalide was kindly provided 
by Marianne S. de Carvalho and Robert S. Jacobs  (University of 
California at Santa Barbara). 
Platelets, Target Cells, and Cytotoxicity Assay.  5-8-wk-old AKR/J 
mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME), and platelets and C5-deficient plasma were isolated as previ- 
ously described in detail (2), except as noted below. We used acid 
citrate dextrose anticoagulation buffer in collecting mouse blood 
in order to improve the yield of platelets.  Plasma was collected in 
a heparinized syringe, 15 U in 150 #1 saline per ml blood. SRBC 
(designated as E) were obtained from a local dealer at 2-wk intervals, 
washed  and  loaded  with  SlCr (Amersham  Corp.,  Arlington 
Heights, IL), sensitized with rabbit polyclonal anti-SRBC antiserum 
and mouse C,~3b  (where indicated;  denoted as EAC,~3b),  and 
stored at 4~  in veronal buffered saline before lytic assay as de- 
scribed (2). Cytotoxic activity by platelets was determined by meas- 
uring Cr release over a 2-h incubation at 37~  unless otherwise 
indicated (2).  As noted, each data point represents the mean of 
several replicate experiments, and error bars indicate the sample SD. 
PLA2 Assay.  PLA2 activity was  measured essentially  as de- 
scribed (25). Briefly, for each sample, 0.25/zCi [arachidonyl-l-14C] 
t-c~-l-palmitoyl-2-arachidonyl  phosphatidylchline  (52.8  mCi/ 
mmol; Dupont New England Nuclear, Boston, MA) was dried 
under a stream of nitrogen, and suspended in 2/xl DMSO followed 
by 98/zl assay buffer (100 mM Tris pH 9.0, 5 mM CaC12, 1 rag/ 
ml fatty acid-free BSA; Sigma Immunochemicals) by vortexing and 
brief sonication in a bath sonicator.  This mixture was added to 
5  x  107 platelets  or frozen and thawed platelets  suspended  in an 
equal volume of assay buffer. The reaction proceeded at 37~  for 
60 rain and was  stopped by freezing samples at  -70~  Subse- 
quently, thawed samples were extracted in chloroform and meth- 
anol (26) and samples in organic phase were spotted on predeve- 
loped silica gel thin layer chromatography plates  (prescored  HL 
uniplates;  Analtech Inc., Newark, DE). Plates were developed in 
120:80:10:4  chloroform/methanol/ammonium  hydroxide/water. 
After autoradiographic exposure (X-Omat film; Eastman Kodak, 
Rochester, NY) to localize spots,  silica plates  were scraped,  and 
the conversion of phosphatidylcholine by PLA2 to free arachidonic 
acid was determined by scintillation counting. 
Arachidonic Acid Release Assay.  25/zCi of [5, 6, 8, 9,  11, 12, 
14, 15AH] arachidonic acid (1 mCi/ml solution in toluene; Amer- 
sham Corp.) was dried under nitrogen, suspended  in 10/~1 eth- 
anol, added to 1 ml platelets at 2  x  10S/ml, and incubated 90 rain 
at 37~  to allow metabolic incorporation into platelet phospholipids. 
Platelets were centrifuged at 13,000g for 15 min at 4~  resuspended 
and washed again,  and diluted to 4  x  107/ml. Incorporation was 
20-40%. Labeled platelets, 25/~1, were added to a chilled multiwell 
plate with 25 #1 target cells per well and shaken at 37~  for 2 h 
as described (2). Samples were diluted fourfold with cold buffer, 
centrifuged at 6,900 g for 15 rain at 4~  and both total radioac- 
tivity and that in the supernatant were determined to calculate per- 
cent release. Results are presented as percent increases in arachi- 
donic acid released from platelets incubated with sensitized  target 
cells (EACm3b), compared with unsensitized control target cells 
(E); percent increase  =  100  x  [(percent release sample  -  percent 
release control/(percent release control)]. As a control, we deter- 
mined the amount of arachidonic  acid released from platelets  in- 
cubated with no target cells; this was 11% of incorporated arachi- 
donic acid. The release from platelets incubated at the highest ratio 
of unsensitized target cells (E) to platelets  (0.5:1) was  9%. 
Lipid Loading.  A concentrated solution of lysophospholipid in 
ethanol was diluted 100-fold with a suspension of platelets at 2  x 
10Vml at 4~  while vortexing, and incubated 60 min on ice to 
minimize metabolic conversion of loaded lipids. Platelets were cen- 
trifuged at 13,000 g for 15 rain at 4~  supernatants  were decanted, 
and  platelets  were  resuspended  to  original  volumes  with  cold 
Tyrode's-gel-EDTA  before addition to target cells. Cytolysis was 
measured by Cr  release over 60 min  at  37~  as described  (2). 
Lysophosphatidylethanolamine,  lysophosphatidylcholine,  lysophos- 
phatidic acid, lysophosphatidylserine, lysophosphatidylinositol,  and 
free arachidonic  acid were purchased from Serdary Research Lab- 
oratories (London, Ontario, Canada); platelet activating factor (PAF) 
and lyso-PAF were from Fluka Chemical Corp. (Ronkonkoma, NY). 
Electron Microsco~.  Mixtures of platelets and target cells were 
incubated for various periods, centrifuged, fixed in cacodylate buffer 
containing 4% glutaraldehyde,  and processed for electron micros- 
copy, as described  (2), 
Fixation of  Platelets.  Platelets were incubated with indicated con- 
centrations of paraformaldehyde in Tyrode's buffer for 15 min at 
6~  Fixative was removed by passing  platelets  over a Sepharose 
CL-2B column (Pharmacia  LKB Biotechnology, Piscataway, NJ; 
27), followed by centrifugation as an additional washing step. The 
platelets were resuspended with no observable dumping in Tyrode's- 
geI-EDTA. 
Serotonin Release Assay.  [3H]Serotonin  (29.5  Ci/mmol,  ~30 
pmol/#l; Dupont New England Nuclear) was added to platelets 
at 2.2  x  10S/ml to a final concentration of 1 pmol//~l, incubated 
at 37~  for 30 min, centrifuged at 13,000g for 10 rain, and washed 
twice in Tyrode's buffer.  Aliquots of platelets  were fixed in 5% 
(wt/vol) paraformaldehyde and washed as described above. Loaded 
platelets were incubated  at 1.5  x  10S/ml with thrombin, A23187, 
target cells or buffer (as indicated) for 15 rain, centrifuged at 13,000 g 
for 10 min, and radioactivity in supernatants and pellets  (solubi- 
lized in Triton X-100) was determined by scintillation counting 
(28). Similar results were obtained in three separate experiments. 
Results 
PLA2 Inhibitors Block Platelet  Cytotoxicity.  Several com- 
pounds have been shown to inhibit PLA2 activity by differ- 
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Figure  1.  Inhibition  of lysis  by PLA2 inhibitors. Each point represents 
the mean of four experiments, and error bars indicate  the sample SD. (a) 
Platelets at 7 x  107/ml were incubated with various concentrations  of 
BPB (m) for 90 min at 25"C. Target  cells (EAC~3b) were added and lysis 
was assayed  as described  (2). As a control, BPB without  platelets  was added 
to target cells (F-q). Similar  results were obtained with BAP, a chemical 
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ent  chemical  mechanisms  (29).  BPB  irreversibly  inhibits 
PLAz by forming a covalent bond to a histidyl residue in the 
active site (30).  Mepacrine is believed to prevent hydrolysis 
of phospholipid substrates by perturbing the substrate-enzyme 
interface (31). Manoalide is a relatively new PLA2 inhibitor 
isolated from sponges that covalently modifies selective ly- 
sine  residues,  inactivating PLA2 from a variety of sources 
(32). Although most careful biochemical experiments to date 
involve inhibition of purified enzymes, correlations between 
in vitro inhibitor efficacy and in vivo functions have also been 
established (33,  34).  We tested the effect of these various 
PLA2 inhibitors on the lytic reaction, first by preincubating 
intact platelets with the compounds. As shown in Fig.  1, 
BPB, mepacrine, and manoalide all inhibit platelet cytotox- 
icity. BAP, a chemical analog of BPB with a similar mode 
of action, also  inhibits platelet lysis (see Fig.  2). 
Each of the compounds tested has been shown previously 
to have pleiotrophic effects. BPB (IDs0  -  30-100/zM) and 
mepacrine (IDs0  =  0.1-0.3 mM) have been documented to 
inhibit phosphatidyl inositol-specific phospholipase C, and 
BPB also antagonizes diglyceride lipase (35, 36). Manoalide 
may also inhibit calcium mobilization and phospholipase C 
(37, 38). However, each of these compounds respectively in- 
hibits platelet cytotoxicity in the appropriate concentration 
ranges documented to be necessary for PLA2 inhibition (Fig. 
1;  22,  29,  33,  34). 
Inhibition of platelet cytotoxicity is greatest with freshly 
isolated platelets.  We found that platelets stored for several 
weeks at 4~  consistently and specifically lysed target cells, 
but that the lytic reaction with stored platelets generally was 
not as efficiently inhibited as described above (data not shown). 
We speculate that the products of PLA2 may spontaneously 
accumulate with prolonged storage at 4~  so that inhibi- 
tors  would  fail  to  block  cytotoxicity since  the  required 
product(s) would already have been formed. 
PLA2 Inhibitors Act on Platelets and Not Target Cells.  De- 
struction of target cells by some effector cells has been shown 
to include a programmed series of reactions leading to lysis 
of the target cells, which presumably could include activa- 
tion of target cell PLA2. Sheep erythrocyte membranes have 
shown to possess PLAz activity (39).  To exclude the possi- 
bility that the PLA2 activity involved in platelet cytotoxicity 
is localized in target cells, we preincubated either platelets 
or  target  cells  with  PLAz  inhibitors,  BPB  or  BAP. The 
treated cells were washed and the corresponding untreated 
target cells or platelets were added to assess lytic function. 
As shown in Fig. 2, pretreatment of platelets results in irre- 
versible inhibition of cytotoxicity. Pretreatment of target cells 
at similar concentrations followed by washing results in vir- 
tually no inhibition of lysis, thereby showing that PLA2 in- 
analog of BPB (see Fig. 2). (b) The effects  of mepacrine were determined 
as in (a), except that platelets at 6 x 107/ml  were pretreated for 60 rain 
before assay  for cytotoxicity  (11). As a control,  mepacrine  without  platelets 
was added to target cells (I-q). (c) Platelets at 5 ￿  10S/ml  were treated 
with the indicated  concentrations  of manoalide  for 30 min at 37~  The 
platelets were diluted 10-fold, added to target cells, and lysis  was assayed 
(11). A a control,  manoalide  without  platelets  was added  to target  cells  ([]). 
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Figure 2.  PLA2  inhibitors act on platelets and not target cells. Various 
concentrations  of BPB (squares)  or RAP (triangles)  were  added to platelets 
(solid  symbols)  or target cells (EAC"~3b; open  symbols)  for 2-h pretreatment 
at 37~  The pretreated  platelets or target cells were washed. Untreated 
platelets or target cells were added to pretreated  target cells or platelets, 
respectively,  and lytic activity was determined.  Each point represents  the 
mean of four experiments, and error bars indicate SD. 
hibitors act irreversibly on platelets and not on target cells. 
Although target cells contain PLA2 activity (39),  the PLA2 
activity relevant in platelet cytotoxicity is found in platelets. 
Correlation between Inhibition of PLA2 Enzymatic Activity 
and Inhibition of Cytotoxicity.  We sought to strengthen the 
hypothesis that PLA2 activity is required in platelet cytotox- 
icity, by determining whether or not BPB affects both enzy- 
matic activity and lytic function, in the same concentration 
range and with parallel  dose-response curves (33).  We ini- 
tially determined the amount of PLA2 activity in various 
platelet preparations by measuring the formation of arachidonic 
acid by platelet extracts incubated with [14C-arachidonyl]-t- 
oe-l-palmitoyl-2-arachidonyl-phosphatidylcholine according 
to the method of Kramer et al. (25). As expected, the measured 
PLA2 activity increased linearly with increasing platelet  con- 
centration, with intact platelets possessing more total enzy- 
matic activity than isolated platelet membranes, even though 
both preparations are effective in lysing target cells (2). Fur- 
thermore, both platelet cytotoxicity and PLA2 activity, as 
measured by formation of free fatty acid, increase in parallel 
with increasing platelet doses (data not shown). 
To establish that BPB inhibits platelet cytotoxicity by in- 
hibiting PLA2 activity, we compared inhibition curves for 
the two effects. As shown in Fig. 3 a, the cytotoxicity by 
intact platelets treated with BPB and then washed, and by 
platelet membranes treated with BPB  and washed, are in- 
hibited to the same degree. The results indicate substantial 
inhibition of cytotoxicity caused by platelet membranes, as 
was the case with BPB-treated washed or unwashed intact 
platelets (Figs.  1 and 2). 
We determined PLA2 activity of these treated platelets  or 
platelet membranes as described above. As shown in Fig. 3 b, 
increasing doses  of BPB  progressively diminish  PLA2  ac- 
tivity as measured by separation of products by thin layer 
chromatography followed by radioautography. The correla- 
tion  between  the  inhibition  of cytotoxic activity  and  of 
PLA2  activity  by  BPB  is  shown  for  frozen  and  thawed 
platelet membranes in Fig. 3 c, and for intact platelets in Fig. 
3 d. Both total enzymatic activity and cytotoxic function are 
inhibited  over  comparable  concentration  ranges,  and  the 
dose-inhibition curves are approximately parallel over a 5-20- 
fold concentration range, in particular for the isolated platelet 
membranes (Fig.  3 c). It is possible  that the decreased total 
PLA2 activity in the partially purified membranes compared 
with that in intact platelets is more directly relevant to the 
cytotoxic reaction and more easily accessible to inhibition by 
exogenous BPB, accounting for the good correlation between 
inhibition  of membrane PLA2 activity and of cytotoxicity 
(Fig.  3,  b and c). 
Free Arachidonic Acid, a Product of PLA2 Action, Is Formed 
and Released by Platelets during the Lyric Reaction.  Given the 
above results  with  PLA2 inhibitors,  we  sought  to  obtain 
more direct evidence indicating platelet PLA2 activation trig- 
gered by EAC"o3b target cells. Thus platelets were loaded 
with radiolabeled arachidonic acid and then incubated with 
various target cells. Supernatants were collected and the amount 
of released arachidonic acid determined as shown in Fig.  4. 
In comparison to the amount of arachidonic acid formed and 
released by platelets incubated with unsensitized E target cells, 
platelets incubated with EAC'~,3b  released almost twice as 
much free fatty acid. The results indicate that platelet PLA2 
is activated by EAC,~3b  target cells. 
Previously, a relationship has been described between FceR 
ligation  and PLA2 activation.  Furthermore, PLA2 activity 
and Fc3"2bR have been copurified (15, 16, 19). To determine 
the relative role of receptors for antibody (FcR) in activating 
PLA2, we determined whether or not target cells sensitized 
with antibody alone (EA) would also trigger arachidonic acid 
release by platelets.  As shown in Fig. 4, platelets do not re- 
lease more arachidonic acid when incubated with EA as com- 
pared with E target cells. Similar results were obtained when 
target cells were sensitized with monoclonal IgG2a or IgG2b 
anti-SRBC antibodies. Both IgG2a and IgG2b were individ- 
ually effective in triggering arachidonate release by platelets 
only when target cells were also sensitized with complement 
(data not shown). In only 2 out of 16 determinations using 
target cells sensitized with monoclonal or polyclonal anti- 
SRBC antibodies, platelet arachidonate release was in fact in- 
creased, in contrast to the usual case described above (Fig. 
4). We have previously shown that neither ligation of FcR 
alone, nor of CR alone, is sufficient to trigger efficient target 
cell lysis. Simultaneous ligation of FcR and CR is required 
for platelet cytotoxicity (2). The present results suggest that 
ligation of receptors not only for Fc but also for complement 
is required, to trigger both efficient PLA2 activity and cy- 
totoxicity (Fig.  4). 
Inhibition of Lysophospholipid Reacylation Increases Platelet Cy- 
totoxicity.  EMTS (thimerosal) has been shown to inhibit acyl 
CoA:lysophosphatide acyltransferase, which catalyzes the for- 
mation of phospholipids  from lysophospholipids  and free fatty 
acids (40). We reasoned that inhibition of platelet acyltrans- 
940  PLA2 Requirement  in Platelet Cytotoxicity Figure  3.  Correlation between inhibition of plateht PLA2 activity and inhibition of cytotoxicity. (a) The relationship between cytotoxicity and 
PLA2 inhibitor concentration was determined as in Fig. 1 under different assay conditions. Platelets (5  x  10S/m1) were pretreated with various concen- 
trations of BPB in DMSO for 30 min at 37~  and then assayed at 2.5  x  107/ml with target cells. The various lyric assay conditions are defined 
as follows: platehts added directly to EAC"~3b target cells (I); washed and then added to target calls (F]); frozen and thawed for three cycles, washed, 
and then added to target cells (i);  or added directly to unsensitized E target cells (A). Lysis was then assayed. Results of the lyric assay are shown 
as the mean of five replicate experiments, and error bars indicate the sample SD.  (b) An autoradiograph of radiolabeled  phospholipids separated by 
thin layer chromatography,  after inhibition of platelet membrane PLA2 by various doses of BPB. (Arrows) Relative migration of substrate  (phosphatidyl- 
choline,  large open arrow), product (arachidonic  acid, single  solid arrow), and origin (double arrows). Lanes are designated as follows: I, no phtelets; 2-4, 
control platelets without BPB, at 0.25,  0.5, or 1 x  final cell concentration; 5-12, platelet membranes pretreated with BPB and then washed;  5, 22/zM 
BPB; 6, 16 #M; 7, 12/zM; 8, 9/zM; 9, 7/*M; 10, 5/~M; 11, 4 #M; 12, 3/~M. (c) Comparison of inhibition by BPB of platelet membrane cytotoxicity 
(I)  and PLA2 activity (D). The PLA2 activity of platdet membranes,  obtained by three cycles of freezing and thawing (2) and treated with various 
concentrations of BPB, was determined as in Fig. 3 b, followed by scraping of the silica gel (between single lines as depicted on autoradiograph), and 
quantitation of radioactivity  by scintillation counting. We defined 100% inhibition to occur when no platelets were added. (d) Comparison of inhibition 
by BPB of intact platelet cytotoxicity (.)  and PLA2 activity (t-I), determined as shown in (b) but using intact platelets. 
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Figure 4.  Arachidonic  acid is released by radiolabeled  platelets incubated 
with EAC,'o3b but not E or EA target cells. Platelets were loaded with 
tritium-labeled arachidonic acid for 60 min at 37~  washed, and incubated 
with EAC~3b target cells (I) or EA target cells (I-]) for 60 rain at 37~ 
Samples were centrifuged at 6,900 g for 15 min, and the amount of radio- 
active arachidonic acid in sample supernatants and pellets was determined 
by scintillation counting. Results are presented as the percent increase in 
arachidonate release over that triggered by unsensitized E target cells. Each 
point represents the mean of five replicates, and error bars indicate the 
sample SD. 
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Figure 6.  Platelet cytotoxictty is increased by exogenous lyso-PAF. 
Platelets at 2  x  107/ml were preincubated on ice for 60 rain with indi- 
cated doses of exogenous lyso-PAF, washed, and then tested for lytic ac- 
tivity (IlL As a control, buffer without  platelets was also tested (V]). 
With no added lyso-PAF, lysis of EAC'~3b by platelets was 44%,  and 
lysis of E was 6%. We calculated changes in lysis due to exogenous lyso- 
PAF as defined in Materials and Methods, as for arachidonic acid release. 
Each point represents the mean of five replicates, and error bars indicate 
the sample SD. 
ferase activity would trap the products of PLA2,  and there- 
fore enhance pellet cytotoxicity. The effect of treatment with 
EMTS is shown in Fig. 5. The results show that platelet cy- 
totoxicity is specifically and substantially increased when EMTS 
is  added  at  appropriate  concentrations  (40). 
Exogenous Lysophospholipids, but Not Free Arachidonic Acid, 
Increase Platelet Cytotoxicity.  To elucidate which of the prod- 
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Figure 5.  Platelet  cytotoxicity is increased by an inhibitor of acyl trans- 
ferase. Various doses of EMTS were added to platelets at 5 x  107/ml (11) 
or buffer ([~), EAC'v3b target cells were added, and lyric activity was 
assayed. To establish further the specificity of this drug's effect, we added 
unsensitized target cells (E) to platelets at 5 x  107/ml (A) or buffer (A). 
Each point represents mean of four experiments, and error bars indicate 
sample SD. 
ucts  of PLAt activation  is (or are) responsible for cytotox- 
icity, we pretreated platelets with various products,  i.e., ex- 
ogenous  lysophospholipids  and/or  arachidonic  acid,  before 
assay for target ceil lysis. As shown in Fig. 6, platelets that 
have been pretreated with lyso-PAF, and then washed, more 
potently lyse EAC"~3b target cells than did untreated platelets. 
Neither pretreated  nor untreated  platelets lyse unsensitized 
E  target cells (Fig.  6). Based on these results, we compared 
the enhancement  of lysis caused by various other lysophos- 
pholipids  preincubated with platelets at 6  pM followed by 
washing.  Exogenous lysophosphatidycholine  is most effec- 
tive, followed by lyso-PAF (Fig. 6), lysophosphatidylinositol, 
lysophosphatidylserine,  and lysophosphatidylethanolamine. 
Exogenous lysophosphatidic acid and PAF are not active under 
these  conditions  in  increasing  platelet  cytotoxicity. 
In contrast  to the results with lysophospholipids,  lysis is 
not specifically increased when arachidonic acid is added. Ar- 
achidonic acid is most likely the predominant fatty acid that 
is released upon PLAt activation in stimulated cells (41, 42). 
Thus although arachidonic acid is specifically released as one 
of the  products  of  PLA2  activation  in  platelets  (Fig.  4), 
when added alone it does not increase the lyric reaction. Fur- 
thermore,  inhibitors  of cyclooxygenases  or  lipoxygenases, 
modifiers of arachidonic  acid that are active in many other 
intercellular processes, have had no consistent effect on platelet 
cytotoxicity  (43;  data  not  shown). 
Although we have shown that platelet cytotoxicity is in- 
creased when platelets are pretreated with lysophospholipids, 
and  that platelets release arachidonic  acid upon  interaction 
with EAC,'o3b target cells, labeling experiments have not re- 
vealed which  or how much lysophospholipid  is formed in 
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 the course of the lytic reaction. It is possible that small local 
changes in the concentration of lysophospholipids triggered 
upon ligation  of FcR and CR  in platelet  membranes are 
sufficient to cause target cell lysis, and that these changes were 
not detected. Lysophospholipids might be more labile than 
free fatty acids that are released,  i.e., lysophospholipids may 
be metabolized before extraction and analysis of platelet lipids 
(44,  45). 
Ultrastructural Analysis of the Lytic Reaction.  Lysophospho- 
lipids are amphoteric molecules with weU-known inherent 
lytic properties,  and have been studied widely as fusogens 
(46). These molecules have been used in constructing hybrid- 
omas and in permeabilizing cells to facilitate incorporation 
of exogenous material (47-49). 
To obtain uhrastructural evidence that membrane fusion 
may occur during the lytic reaction, mixtures of platelets and 
EAC',~3b or E target cells coincubated for various periods 
were examined by transmission  electron microscopy. The 
results are shown in Fig.  7.  As shown in Fig.  7 A,  when 
platelets are incubated with EAC"o3b target cells, changes 
in platelet morphology are visualized after only 50 min incu- 
bation. The delineation between platelet and target cell mem- 
branes is increasingly difficult to resolve as the lytic reaction 
proceeds. The platelet cytoplasm has become more electron 
dense and attained a density similar to that of the target cell 
contents (predominantly hemoglobin), possibly suggesting 
that target cell hemoglobin has leaked into platelets.  By con- 
trast, platelets incubated with unsensitized target cells (E) 
do  not  become  more electron dense even  after  130  min 
(Fig.  7 B). 
Leakage of SlCr-modified hemoglobin into the superna- 
tant is measured in the lytic assay (2).  Samples were taken 
at  0,  50,  90,  and  130  min  for  electron microscopy and 
for determination of cell lysis by SlCr release.  The lysis of 
EAC"-3b is 11,  14, 69, and 70%, respectively.  The lysis of 
control E by platelets is <16%  during the entire 130-min 
period. Thus, electron-dense platelets become apparent be- 
fore there is significant release of hemoglobin into the super- 
natant (Fig.  7 A). Less than 1% of platelets incubated with 
unsensitized E target cells are electron dense (Fig. 7 B). The 
results suggest that before target cell lysis occurs, a platelet- 
to-target cell communication may be established. 
It is notable that platelet granules remain morphologically 
intact in platelets even after substantial target cell lysis has 
occurred (Fig.  7 A, and data not shown). In the following 
section, we present additional biochemical evidence that de- 
granulation is not required and does not occur during the 
cytotoxic reaction. 
Effect of Fixation on Platelet Degranulation and Lysis.  We 
showed previously that platelets lyse target cells bearing ap- 
propriate Fc and complement components most efficiently 
when these ligands are closely apposed. The results indicated 
that platelet receptors for IgG and complement must exist 
in close physical proximity, perhaps in a physical complex (2). 
As shown in Fig. 8, platelets can be fixed in up to 10% 
(wt/vol) paraformaldehyde at 6~  for 15 min without loss 
of specific recognition or cytotoxic function. These fixation 
￿9 4iLL______  2 
0  1  2  3  4  5 
platelets  /  mL,  x  10  .7 
Figure  8.  Effect  of paraformaldehyde fixation on platdet-mediated  lysis. 
Platelets were treated with 10% wt/vol (A), 5% (D), or no (A) parafor- 
maldehyde at 8  x  10" cells/m1 in Tyrode's solution  for 15 rain  at 6~ 
washed, EAC'~3b target cells were added, and target cell lysis was deter- 
mined.  Each point represents  the mean  of four experiments,  and error 
bars indicate sample SD. The lysis of unsensitized target cells, E, by unfixed 
or fixed platelets  was <10%. 
conditions are sufficient to inhibit lateral diffusion of inte- 
gral membrane proteins in other mammalian cells as mea- 
sured by immunofluorescence localization (50). Presumably, 
platelet FcR, CR, and PLA2 lie in close physical proximity 
Table  1.  Lack of Platelet Degranulation after Fixation or during 
the Lytic  Reaction 
[3H]Serotonin  release 
percent change (vs. control) 
Platelets  Platelets fixed in 
Treatment  not fixed  5%  paraformaldehyde 
Control  0  0 
A23187,  10  nM  10  -  3 
A23187,  100  #M  93  -  3 
Thrombin,  100  nM  7  -  3 
Thrombin,  10  #M  93  -  2 
E  target  cells  3  -6 
EAC~3b  target  cells  0  -6 
Lack of platelet degranulation  during the lytic reaction or after fixation. 
Platelets at 2  x  lOS/ml were preloaded with [3H]serotonin,  washed,  in- 
cubated  in 5 or 0% paraformaldehyde  for 15 min at 6~  and washed 
again. Calcium ionophore A23187, thrombin, or target cells were added 
before incubation for 15 min at 25~  Reaction mixtures were centrifuged 
and  radioactivity  in the supernatants  and pellets was  measured.  Spon- 
taneous  serotonin  release was  22%  from unfixed  and 32%  from fixed 
platelets,  respectively. Similar results were obtained in three independent 
trials. 
944  PLA2 Requirement in Platelet  Cytotoxicity before interaction with target ceils, perhaps in a preformed 
complex associated with platelet membranes that is unper- 
turbed even under relatively stringent fixation conditions. This 
is consistent with previous observations that FcR and PLA2 
copurify from human and mouse cells, that FcR and CR. cocap, 
and that FcK exists in an aggregated state in situ in other 
cell types (15-16,  51, 52). 
We previously showed that isolated platelet membranes, 
obtained by freezing and thawing or by sonicating platelets, 
are sufficient to cause efficient and specific target cell lysis 
(2).  We were interested, however, in determining whether 
or not platelet degranulation is required for cytotoxicity, since 
PLA2 activation has been correlated with degranulation (53). 
Therefore, platelets were preloaded with radiolabeled sero- 
tonin, washed, and then incubated with various target cells. 
As a control, the radiolabeled platelets were treated with two 
known secretagogues, thrombin and A23187. As shown in 
Table 1, serotonin is released in the presence of thrombin or 
A23187, indicating degranulation of platelet-dense granules. 
However, platelets do not release serotonin when incubated 
with E or EAC*3b target cells, showing that degranulation 
does not occur during the cytotoxic reaction (Table 1). As 
an additional control, we verified that serotonin loading does 
not  affect  platelet  cytotoxicity  (data  not  shown).  When 
platelets are fixed with 5% paraformaldehyde, no serotonin 
release occurs in the presence of thrombin or A23187 (28), 
even though target cell lysis is unaffected (Fig. 8). These results 
further substantiate our previous evidence that the complete 
cytotoxic system is localized in platelet membranes (2), prob- 
ably as a preformed complex. 
Discussion 
By using a set  of PLA2 inhibitors  and correlating  bio- 
chemical activity with function, we have shown that PLA2 
is required for platelet cytotoxicity. This is further corrobo- 
rated by the enhancement of lysis observed in the presence 
of an inhibitor of acyltransferase, which catalyzes a reaction 
opposing that of PLA2. Additional support for the activa- 
tion of PLA2 comes from the concentration-dependent re- 
lease of arachidonic acid by platelets when they are incubated 
with appropriate EAC~3b but not E or EA target cells. We 
were not able to detect concomitant formation of lysophos- 
pholipids upon interaction with target cells, possibly because 
of the lability of these lytic molecules (44, 45). This possi- 
bility is consistent with the fact that unsensitized bystander 
cells are not lysed even while lysis of appropriately sensitized 
target cells is underway (2). However, the fact that platelets 
pretreated with lysophospholipids but not arachidonic acid 
lyse target cells more efficiently suggests that lysophospholipids 
are the active lytic molecules generated during the lytic reac- 
tion.  It is interesting that schistosomula have been shown 
to release lysophosphatidylcholine in lysing adherent host 
RBC,  although the rate of release is small (54). 
We previously demonstrated that efficient target cell lysis 
is triggered by membrane-bound IgG (complement-fixing sub- 
classes IgG2a,  IgG2b, and IgG3) and complement compo- 
nents C"~3b (2).  The fact that target cells were lysed when 
sensitized with IgG and C'x,3b, but not with IgM and C'~3b 
followed by IgG, suggests that bound IgG and C"~3b must 
be in close physical proximity for the lytic reaction to occur. 
The evidence that fixed platelets can lyse sensitized target cells 
(Fig. 8) extends the idea that the complete cytotoxic system 
resides in platelet membranes, suggesting that receptors for 
Fc  and  complement  and  membrane-associated  PLA2  may 
exist as preformed complexes in platelet membranes. 
It is not clear at this time whether ligation of FcyR and 
CR directly activates a closely associated PLA2, or if there 
exists an intermediate factor required for activation of the 
lipase. Evidence in favor of both possibilities has been ob- 
tained using other cells.  Suzuki et al.  (15,  16) found that 
PLA2 activity and Fc3'R copurify from B cells and macro- 
phages. Narasimhan et al.  (19) showed that activation of a 
G  protein intermediate is required for PLA2 activation by 
FceR in basophils.  Recent evidence suggests that other li- 
pase activities may also be triggered by platelet Fc receptor 
ligation (55). 
We previously showed that  platelet  cytotoxicity occurs 
efficiently in a plasma-free system, where platelets are washed 
and incubated in Tyrode's buffer containing gelatin and 4 mM 
EDTA (2). It is notable that most of the known PLA2 iso- 
zymes require calcium (56), although exceptions have been 
described (57). The incubation buffer used in this system at 
pH •7.4  contains at least micromolar amounts of free cal- 
cium, despite added EDTA (57, 58; and Symer, D. E., unpub- 
lished observations). Therefore, the presence of EDTA in this 
experimental system does not contradict the proposed involve- 
ment of a membrane-associated PLA2 in the lytic reaction. 
Progress in molecular biology has facilitated elucidation 
of the structure and localization of Fc receptors and comple- 
ment  receptors,  and  now  there  is  evidence  that  distinct 
receptors utilizing common receptor subunits and signaling 
pathways exist in disparate cells of different species (18,  20, 
59). Similarities in the inhibition of NK ceU-mediated cyto- 
toxicity by PLA2 inhibitors  suggest that  a similar mecha- 
nism of cytotoxicity, caused by lysophospholipid generation, 
may exist in those cells as well (22-24). 
If lysophospholipids are formed as a result of contact with 
sensitized target cells, and if these lytic molecules behave as 
fusogens in vivo, as observed in vitro (48) and as suggested 
by electron microscopy of the platelet lytic reaction (Fig. 7), 
then it may be possible to deliver cytotoxic drugs to antibody- 
coated  target  cells  by  preloading  the  platelet  cytoplasm. 
Lysophospholipids have been used to mediate fusion of lipo- 
somes with intact ceils (48, 60).  It may also be possible to 
increase antibody-dependent cytotoxicity by increasing the 
products  of  platelet  membrane--associated  PLA2  activity 
using various exogenous inhibitors (Fig. 5). Further elucida- 
tion of the mechanism of antibody-dependent platelet cyto- 
toxicity will facilitate some of these goals. 
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